These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 21376583

  • 1. Discovery of triazine-benzimidazoles as selective inhibitors of mTOR.
    Peterson EA, Andrews PS, Be X, Boezio AA, Bush TL, Cheng AC, Coats JR, Colletti AE, Copeland KW, DuPont M, Graceffa R, Grubinska B, Harmange JC, Kim JL, Mullady EL, Olivieri P, Schenkel LB, Stanton MK, Teffera Y, Whittington DA, Cai T, La DS.
    Bioorg Med Chem Lett; 2011 Apr 01; 21(7):2064-70. PubMed ID: 21376583
    [Abstract] [Full Text] [Related]

  • 2. Structure-based optimization of morpholino-triazines as PI3K and mTOR inhibitors.
    Poulsen A, Williams M, Nagaraj HM, William AD, Wang H, Soh CK, Xiong ZC, Dymock B.
    Bioorg Med Chem Lett; 2012 Jan 15; 22(2):1009-13. PubMed ID: 22197143
    [Abstract] [Full Text] [Related]

  • 3. Synthesis and structure-activity relationships of dual PI3K/mTOR inhibitors based on a 4-amino-6-methyl-1,3,5-triazine sulfonamide scaffold.
    Wurz RP, Liu L, Yang K, Nishimura N, Bo Y, Pettus LH, Caenepeel S, Freeman DJ, McCarter JD, Mullady EL, Miguel TS, Wang L, Zhang N, Andrews KL, Whittington DA, Jiang J, Subramanian R, Hughes PE, Norman MH.
    Bioorg Med Chem Lett; 2012 Sep 01; 22(17):5714-20. PubMed ID: 22832322
    [Abstract] [Full Text] [Related]

  • 4. Discovery and SAR exploration of a novel series of imidazo[4,5-b]pyrazin-2-ones as potent and selective mTOR kinase inhibitors.
    Mortensen DS, Perrin-Ninkovic SM, Harris R, Lee BG, Shevlin G, Hickman M, Khambatta G, Bisonette RR, Fultz KE, Sankar S.
    Bioorg Med Chem Lett; 2011 Nov 15; 21(22):6793-9. PubMed ID: 21978683
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Identification of 2-oxatriazines as highly potent pan-PI3K/mTOR dual inhibitors.
    Dehnhardt CM, Venkatesan AM, Chen Z, Delos-Santos E, Ayral-Kaloustian S, Brooijmans N, Yu K, Hollander I, Feldberg L, Lucas J, Mallon R.
    Bioorg Med Chem Lett; 2011 Aug 15; 21(16):4773-8. PubMed ID: 21763134
    [Abstract] [Full Text] [Related]

  • 10. Discovery of 2-ureidophenyltriazines bearing bridged morpholines as potent and selective ATP-competitive mTOR inhibitors.
    Zask A, Verheijen JC, Richard DJ, Kaplan J, Curran K, Toral-Barza L, Lucas J, Hollander I, Yu K.
    Bioorg Med Chem Lett; 2010 Apr 15; 20(8):2644-7. PubMed ID: 20227881
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A hit to lead discovery of novel N-methylated imidazolo-, pyrrolo-, and pyrazolo-pyrimidines as potent and selective mTOR inhibitors.
    Lee W, Ortwine DF, Bergeron P, Lau K, Lin L, Malek S, Nonomiya J, Pei Z, Robarge KD, Schmidt S, Sideris S, Lyssikatos JP.
    Bioorg Med Chem Lett; 2013 Sep 15; 23(18):5097-104. PubMed ID: 23932790
    [Abstract] [Full Text] [Related]

  • 13. [mTOR inhibitor].
    Muro K.
    Gan To Kagaku Ryoho; 2011 Jan 15; 38(1):7-11. PubMed ID: 21368454
    [Abstract] [Full Text] [Related]

  • 14. 2-Arylthiazolidine-4-carboxylic acid amides (ATCAA) target dual pathways in cancer cells: 5'-AMP-activated protein kinase (AMPK)/mTOR and PI3K/Akt/mTOR pathways.
    Li CM, Narayanan R, Lu Y, Hurh E, Coss CC, Barrett CM, Miller DD, Dalton JT.
    Int J Oncol; 2010 Oct 15; 37(4):1023-30. PubMed ID: 20811725
    [Abstract] [Full Text] [Related]

  • 15. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.
    Marzec M, Kasprzycka M, Liu X, El-Salem M, Halasa K, Raghunath PN, Bucki R, Wlodarski P, Wasik MA.
    Oncogene; 2007 Aug 16; 26(38):5606-14. PubMed ID: 17353907
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. 4-methylpteridinones as orally active and selective PI3K/mTOR dual inhibitors.
    Liu KK, Bagrodia S, Bailey S, Cheng H, Chen H, Gao L, Greasley S, Hoffman JE, Hu Q, Johnson TO, Knighton D, Liu Z, Marx MA, Nambu MD, Ninkovic S, Pascual B, Rafidi K, Rodgers CM, Smith GL, Sun S, Wang H, Yang A, Yuan J, Zou A.
    Bioorg Med Chem Lett; 2010 Oct 15; 20(20):6096-9. PubMed ID: 20817449
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.